CHGCY:OTC-Chugai Pharmaceutical Co Ltd ADR (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 26.42

Change

0.00 (0.00)%

Market Cap

USD 93.38B

Volume

0.12M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; and research collaboration and option to license agreement with Araris Biotech AG to develop ADCs using Araris AraLinQ technology. The company was founded in 1925 and is headquartered in Chuo-ku, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-07 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
RHHBF Roche Holding AG

N/A

USD 248.88B
RHHBY Roche Holding Ltd ADR

N/A

USD 248.79B
RHHVF Roche Holding AG Participation

N/A

USD 248.79B
AZNCF AstraZeneca PLC

N/A

USD 214.99B
SNYNF Sanofi

N/A

USD 127.02B
DSNKY Daiichi Sankyo Co Ltd ADR

N/A

USD 45.22B
ALPMF Astellas Pharma Inc

N/A

USD 17.22B
ALPMY Astellas Pharma Inc

N/A

USD 16.79B
RICFY Recordati Industria Chimica e ..

N/A

USD 14.03B
CSPCY CSPC Pharmaceutical Group Limi..

N/A

USD 8.62B

ETFs Containing CHGCY

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 20.25% 78% C+ 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.25% 75% C 68% D+
Trailing 12 Months  
Capital Gain 75.32% 100% F 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 75.32% 97% N/A 88% B+
Trailing 5 Years  
Capital Gain 10.54% 83% B 61% D-
Dividend Return 10.72% 46% F 27% F
Total Return 21.26% 72% C 58% F
Average Annual (5 Year Horizon)  
Capital Gain -0.11% 60% D- 44% F
Dividend Return -0.09% 47% F 39% F
Total Return 0.02% 4% F 2% F
Risk Return Profile  
Volatility (Standard Deviation) 36.27% 17% F 61% D-
Risk Adjusted Return -0.25% 47% F 40% F
Market Capitalization 93.38B 74% C 99% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.